{"id":801457,"date":"2025-01-16T07:03:50","date_gmt":"2025-01-16T12:03:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/"},"modified":"2025-01-16T07:03:50","modified_gmt":"2025-01-16T12:03:50","slug":"eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/","title":{"rendered":"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WATERTOWN, Mass., Jan.  16, 2025  (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company\u2019s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $7.69 per share, the closing price of EyePoint Pharmaceuticals\u2019 common stock on January 15, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee\u2019s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee\u2019s continued service with EyePoint Pharmaceuticals through the applicable vesting dates.<\/p>\n<p align=\"justify\">\n        <strong>About EyePoint Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company&#8217;s pipeline leverages its proprietary bioerodible Durasert E\u2122 technology for sustained intraocular drug delivery. The Company\u2019s lead product candidate, DURAVYU\u2122 (f\/k\/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E\u2122. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet AMD, the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in DME. EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.<\/p>\n<p align=\"justify\">Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E\u2122 to potentially improve outcomes in serious retinal diseases. The proven Durasert\u00ae drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.<\/p>\n<p align=\"justify\">Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.<\/p>\n<p align=\"justify\">\n        <em>DURAVYU\u2122 has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.<\/em>\n      <\/p>\n<p align=\"left\">\n        <strong>For EyePoint Pharmaceuticals:<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Christina Tartaglia<br \/>Precision AQ<br \/>Direct: 212-698-8700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FAGKYqnS2kIqIreubQJKvkvO1IyfhsnH3Y8dH6qQaDddMZF3_4h5AGH0TwqrCpZCsGlLq9CzXTiBi_Fi6EiXAQLcpHjt4txUwg4nA2B4qCewN8jiA5NXKoqqMajwe6xh9MTx5OuI0y4G4SlZ9zAS5w==\" rel=\"nofollow\" target=\"_blank\">christina.tartaglia@precisionaq.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Amy Phillips<br \/>Green Room Communications<br \/>Direct: 412-327-9499<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_ztSxMT3Fg_ACFk1i71m1G60CDXLn2_v6oLSHhaHhZ-hek5_7Ewzw533rOk8sC5nCTkI6v8gR7AGQYgsYjdTDFwDypKT1ws7UgGoK6HEy1bGxPRWmVMW4i4wHfDYbgdV\" rel=\"nofollow\" target=\"_blank\">aphillips@greenroompr.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWNhMjlmNTEtOGIxYS00YmJiLWE5YjUtNjc0NDU2YTY5MWUxLTEwMTczOTA=\/tiny\/EyePoint-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company\u2019s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-801457","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company\u2019s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ &hellip; Continue reading &quot;EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T12:03:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-01-16T12:03:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/\"},\"wordCount\":498,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/\",\"name\":\"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=\",\"datePublished\":\"2025-01-16T12:03:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company\u2019s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ &hellip; Continue reading \"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-16T12:03:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","datePublished":"2025-01-16T12:03:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/"},"wordCount":498,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/","name":"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=","datePublished":"2025-01-16T12:03:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjgzNSM2Njk2NTE3IzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=801457"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801457\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=801457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=801457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=801457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}